Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Seynaeve

Showing results (81-90 of 175) with videos related to

Pageof 18
Sort By:
Lancet (London, England)|January 21, 2011
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trialCornelis J H van de Velde, Daniel Rea, Caroline Seynaeve, et al.
Breast Cancer Research and Treatment|November 23, 2013
CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trialVincent O Dezentjé, Hans Gelderblom, Ron H N Van Schaik, et al.
The Lancet. Oncology|July 23, 2017
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trialMarloes G M Derks, Erik J Blok, Caroline Seynaeve, et al.
JAMA|February 10, 2012
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancerWillemien van de Water, Christos Markopoulos, Cornelis J H van de Velde, et al.
The New England Journal of Medicine|August 14, 2009
Micrometastases or isolated tumor cells and the outcome of breast cancerMaaike de Boer, Carolien H M van Deurzen, Jos A A M van Dijck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2009
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriersMieke Kriege, Caroline Seynaeve, Hanne Meijers-Heijboer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatmentAnne-Joy M de Graan, Sebastiaan F Teunissen, Filip Y F L de Vos, et al.
International Journal of Cancer|May 3, 2014
Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort studySepideh Saadatmand, Janet R Vos, Maartje J Hooning, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2005
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal studyPeter Nieboer, Ciska Buijs, Sjoerd Rodenhuis, et al.
Breast Cancer Research : BCR|November 14, 2007
Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer casesPetra E A Huijts, Maaike P G Vreeswijk, Karin H G Kroeze-Jansema, et al.
Pageof 18

Showing results (81-90 of 175) with videos related to

Sort By:
Pageof 18
Lancet (London, England)|January 21, 2011
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trialCornelis J H van de Velde, Daniel Rea, Caroline Seynaeve, et al.
Breast Cancer Research and Treatment|November 23, 2013
CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trialVincent O Dezentjé, Hans Gelderblom, Ron H N Van Schaik, et al.
The Lancet. Oncology|July 23, 2017
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trialMarloes G M Derks, Erik J Blok, Caroline Seynaeve, et al.
JAMA|February 10, 2012
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancerWillemien van de Water, Christos Markopoulos, Cornelis J H van de Velde, et al.
The New England Journal of Medicine|August 14, 2009
Micrometastases or isolated tumor cells and the outcome of breast cancerMaaike de Boer, Carolien H M van Deurzen, Jos A A M van Dijck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2009
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriersMieke Kriege, Caroline Seynaeve, Hanne Meijers-Heijboer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatmentAnne-Joy M de Graan, Sebastiaan F Teunissen, Filip Y F L de Vos, et al.
International Journal of Cancer|May 3, 2014
Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort studySepideh Saadatmand, Janet R Vos, Maartje J Hooning, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2005
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal studyPeter Nieboer, Ciska Buijs, Sjoerd Rodenhuis, et al.
Breast Cancer Research : BCR|November 14, 2007
Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer casesPetra E A Huijts, Maaike P G Vreeswijk, Karin H G Kroeze-Jansema, et al.
Pageof 18